Hikma Pharmaceuticals (OTCMKTS:HKMPF) Stock Price Crosses Above Fifty Day Moving Average – Here’s Why

Hikma Pharmaceuticals Plc (OTCMKTS:HKMPF)’s share price crossed above its 50-day moving average during trading on Wednesday . The stock has a 50-day moving average of $19.99 and traded as high as $21.56. Hikma Pharmaceuticals shares last traded at $21.56, with a volume of 607 shares changing hands.

Wall Street Analysts Forecast Growth

Separately, Citigroup initiated coverage on shares of Hikma Pharmaceuticals in a report on Thursday, July 16th. They issued a “buy” rating for the company. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold”.

Hikma Pharmaceuticals Stock Performance

The company has a 50-day simple moving average of $20.04 and a two-hundred day simple moving average of $19.43. The company has a current ratio of 1.82, a quick ratio of 1.06 and a debt-to-equity ratio of 0.57.

Hikma Pharmaceuticals Company Profile

Hikma Pharmaceuticals is a multinational pharmaceutical company that develops, manufactures and markets a broad range of branded and non-branded generics, specialty injectables and consumer healthcare products. The company’s three core business segments include generic medicines, injectable products and branded generics, serving hospitals, wholesalers and pharmacies worldwide. Its product portfolio spans diverse therapeutic areas such as cardiovascular, oncology, respiratory, pain management and anti-infectives, with an emphasis on injectable solutions for complex hospital treatments.

Founded in 1978 in Amman, Jordan, Hikma has grown through organic expansion and strategic acquisitions to become one of the leading pharmaceutical players in the Middle East, North Africa, Europe and the United States.